CTIS.eu › Cities › Germany › Mutlangen
Mutlangen
Germany
37 total trials
14 recruiting
2023-509861-19-00
4
Diffuse large B-cell lymphoma (DLBCL)
2024-519472-69-00
4
CML-Patients in chronic phase having failed a prior attempt to stop im
2024-519504-27-00
5
Relapsed Refractory Multiple Myeloma
2023-507402-13-00
5
2024-04-03
Multiple myeloma
2022-502660-20-00
5
2024-01-23
Follicular lymphoma
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
2024-517131-52-00
5
2025-11-03
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
2023-509861-19-01
4
2025-09-30
High-grade B-cell lymphoma (HGBL)
2023-510294-34-00
5
2025-06-12
small lymphocytic lymphoma (SLL)
2024-515593-27-00
5
2025-05-08
relapsed or refractory mantle cell lymphoma (R/R MCL)
2022-500574-34-00
4
2025-03-21
Waldenström’s Macroglobulinemia
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
2022-502889-24-00
5
2024-02-13
chemotherapy-induced polyneuropathy (CIPN)
2022-503092-28-00
5
2024-01-08
Relapsed/Refractory Follicular Lymphoma
2022-501808-96-00
4
2023-05-15
Mantle Cell Lymphoma
2023-504599-10-00
4
2022-03-29
Chronic lymphocytic leukemia recurrent
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
2023-506139-13-00
5
2024-01-04
Treatment naïve patients with MF
2022-500430-29-00
5
2023-10-11
Myelodysplastic Syndrome (MDS)
2024-511209-49-00
6
2022-04-26
Patients with hormone receptor positive HER2 negative locally advanced
2022-500439-35-00
5
2021-02-11
treatment-naive chronic lymphocytic leukemia
2024-511929-60-00
4
2021-01-28
Waldenström’s Macroglobulinemia
2024-511577-29-01
5
2020-03-13
intermediate and high-risk rectal cancer
2024-511747-25-00
4
2019-12-23
B-cell non-Hodgkin lymphoma (NHL)
Showing 1–24 of 37 trials